Corey L - Search Results

1

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: corey l. Vaccine. 2006 Nov 17;24(47-48):6893-904. doi: 10.1016/j.vaccine.2006.06.009. Epub 2006 Jun 27. Vaccine. 2006. PMID: 16890329

2

Do scarce targets or T killers control primary HIV infection?

Wick D, Self SG, Corey L. Wick D, et al. Among authors: corey l. J Theor Biol. 2002 Jan 21;214(2):209-14. doi: 10.1006/jtbi.2001.2457. J Theor Biol. 2002. PMID: 11812173

3

Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Malhotra U, Holte S, Zhu T, Delpit E, Huntsberry C, Sette A, Shankarappa R, Maenza J, Corey L, McElrath MJ. Malhotra U, et al. Among authors: corey l. J Virol. 2003 Feb;77(4):2663-74. doi: 10.1128/jvi.77.4.2663-2674.2003. J Virol. 2003. PMID: 12552005 Free PMC article.

4

Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection.

Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Cao J, et al. Among authors: corey l. J Virol. 2003 Jun;77(12):6867-78. doi: 10.1128/jvi.77.12.6867-6878.2003. J Virol. 2003. PMID: 12768006 Free PMC article.

5

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. Among authors: corey l. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

6

Dual HIV-1 infection associated with rapid disease progression.

Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, Williamson C, Corey L, Margolick JB, Mullins JI. Gottlieb GS, et al. Among authors: corey l. Lancet. 2004 Feb 21;363(9409):619-22. doi: 10.1016/S0140-6736(04)15596-7. Lancet. 2004. PMID: 14987889

7

Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection.

Fulcher JA, Hwangbo Y, Zioni R, Nickle D, Lin X, Heath L, Mullins JI, Corey L, Zhu T. Fulcher JA, et al. Among authors: corey l. J Virol. 2004 Aug;78(15):7883-93. doi: 10.1128/JVI.78.15.7883-7893.2004. J Virol. 2004. PMID: 15254161 Free PMC article.

8

A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.

de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L. de Bruyn G, et al. Among authors: corey l. Vaccine. 2006 Feb 13;24(7):914-20. doi: 10.1016/j.vaccine.2005.08.088. Epub 2005 Sep 21. Vaccine. 2006. PMID: 16213066 Clinical Trial.

9

How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?

Wick WD, Yang OO, Corey L, Self SG. Wick WD, et al. Among authors: corey l. J Virol. 2005 Nov;79(21):13579-86. doi: 10.1128/JVI.79.21.13579-13586.2005. J Virol. 2005. PMID: 16227278 Free PMC article.

10

Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.

Kim HN, Tabet SR, Corey L, Celum CL. Kim HN, et al. Among authors: corey l. Vaccine. 2006 Jan 23;24(4):532-9. doi: 10.1016/j.vaccine.2005.05.049. Epub 2005 Oct 5. Vaccine. 2006. PMID: 16242816

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,094 results

Search Page

Filters